Related Experiment Video
Updated: Jun 25, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Second and third line treatment in non-small cell lung cancer
Adolfo Favaretto1, Giulia Pasello, Cristina Magro
1U.O. Oncologia Medica 2, Istituto Oncologico Veneto IOV IRCCS, Via Gattamelata 64, 35128 Padova, Italy. adolfo.favaretto@sanita.padova.it
Abstract:
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide, and the advances in second and third line treatment have led to prognostic improvements in the latest years. Besides the two cytotoxic agents, docetaxel and pemetrexed, approved in NSCLC second line treatment, a new class of drugs against specific molecular targets seems to be an alternative to conventional treatment. Many trials are ongoing to assess the activity of new drugs, alone or in association, and new combinations of third-generation chemotherapeutic agents.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
